Login Register Cart 0
Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

An Overview of Antihistamines and their Properties used for Treatment of Different Diseases

Author(s): Riya Chaudhari*, Seema Gosavi, Pratiksha Bornare, Saurabh Sonawane and Tejas Ahire

Volume 22, Issue 4, 2023

Published on: 28 November, 2023

Page: [220 - 229] Pages: 10

DOI: 10.2174/0118715230259623231111165759

Price: $65

Abstract

Background: By comparing the histamine impact to the instant response to an injected foreign protein in previously sensitized animals, one might hypothesize that histamine may be involved in this reaction. Through all four of the recognized types of histamine receptors, histamine is also essential for the control of immunological function and acute and chronic allergic inflammation.

Methods: Recent evidence points to anti-IgE antibodies and specific antibodies to cytokines like IL-4 or IL-5 that are associated with allergic inflammation as probable causes of Allergic Rhinitis. The therapeutic advantage of antihistamines is a decrease in allergy symptoms and any other allergy-related symptoms. We research the many diseases and dose forms in which antihistamines are used. Pediatric age groups have never been thoroughly studied for firstgeneration antihistamines. Oral antihistamines are suggested as the first line of therapy for people with mild to severe intermittent Allergic Rhinitis symptoms.

Results: Currently, approximately 100 different antihistamine-containing medicines and around 20 different H1-receptor antagonists are available for therapeutic use. Antihistamines of the second generation are more efficient and secure than those of the first generation. We conducted a research on the sedative and non-sedative effects of antihistamines used to treat various diseases.

Conclusion: The present investigation highlights the use of antihistamines in various diseases at different ages, their sedative and non-sedative effect, and their utility in treating insomnia based on their safety and current use among the patient population, as well as our observation.

Keywords: Antihistamines, allergic rhinitis, late and early reaction, H1 and H2 receptor, COVID-19, sedative and non-sedative.

« Previous Next »
Graphical Abstract

[1]
Simons, F.E.R.; Simons, K.J. H1 Antihistamines. World Allergy Organ. J., 2008, 1(9), 145-155.
[http://dx.doi.org/10.1097/WOX.0b013e318186fb3a] [PMID: 23282578]
[2]
Parisi, G.F.; Licari, A.; Papale, M.; Manti, S.; Salpietro, C.; Marseglia, G.L.; Leonardi, S. Antihistamines: ABC For the pediatricians. Pediatr. Allergy Immunol., 2020, 31(S24)(Suppl. 24), 34-36.
[http://dx.doi.org/10.1111/pai.13152] [PMID: 32017222]
[3]
Baroody, F.M.; Naclerio, R.M. Antiallergic effects of H 1 ‐receptor antagonists. Allergy, 2000, 55(s64)(64), 17-27.
[http://dx.doi.org/10.1034/j.1398-9995.2000.00803.x] [PMID: 11291777]
[4]
StatPearls [Internet]. treasure island (FL): StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430685/(Accessed on 2023 Jan).
[5]
Montoro, J.; Mullol, J.; Dávila, I.; Ferrer, M.; Sastre, J.; Bartra, J.; Jáuregui, I.; del Cuvillo, A.; Valero, A. Bilastine and the central nervous system. J. Investig. Allergol. Clin. Immunol., 2011, 21(3), 9-15.
[PMID: 22185045]
[6]
Gilboa, S.M.; Ailes, E.C.; Rai, R.P.; Anderson, J.A.; Honein, M.A. Antihistamines and birth defects: A systematic review of the literature. Expert Opin. Drug Saf., 2014, 13(12), 1667-1698.
[http://dx.doi.org/10.1517/14740338.2014.970164] [PMID: 25307228]
[7]
Church, M.; Church, D. Pharmacology of antihistamines. Indian J. Dermatol., 2013, 58(3), 219-224.
[http://dx.doi.org/10.4103/0019-5154.110832] [PMID: 23723474]
[8]
Randall, K.L.; Hawkins, C.A. Antihistamines and allergy. Aust. Prescr., 2018, 41(2), 42-45.
[http://dx.doi.org/10.18773/austprescr.2018.013] [PMID: 29670310]
[9]
Mahdy, A.M.; Webster, N.R. Histamine and antihistamines. Anaesth. Intensive Care Med., 2011, 12(7), 324-329.
[http://dx.doi.org/10.1016/j.mpaic.2011.04.012]
[10]
Çobanoğlu, B.; Toskala, E.; Ural, A.; Cingi, C. Role of leukotriene antagonists and antihistamines in the treatment of allergic rhinitis. Curr. Allergy Asthma Rep., 2013, 13(2), 203-208.
[http://dx.doi.org/10.1007/s11882-013-0341-4] [PMID: 23389557]
[11]
May, J.R.; Dolen, W.K. Management of allergic rhinitis: A review for the community pharmacist. Clin. Ther., 2017, 39(12), 2410-2419.
[http://dx.doi.org/10.1016/j.clinthera.2017.10.006] [PMID: 29079387]
[12]
Meltzer, EO; Rosario, NA; Van Bever, H; Lucio, L Fexofenadine: review of safety efficacy and unmet needs in children with allergic rhinitis. Allergy Asthma & Clinical Immunology., 2021. Dec;17:1-1
[13]
Min, Y.G. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol. Res., 2010, 2(2), 65-76.
[http://dx.doi.org/10.4168/aair.2010.2.2.65] [PMID: 20358020]
[14]
Khashayar, F.; Sarah, S.; Maria, C. . O'Rourke. Antihistamines, StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK538188/# article-17695.s10
[15]
Niels, N.; Allergic, R. Otopathological laboratory, ent department, rigshospitalet. Copenhagen, Denmark., 1979, 34, 195-208.
[16]
Sur, D.K.; Scandale, S. Treatment of allergic rhinitis. Am. Fam. Physician,, 2010, 81(12), 1440-1446.
[PMID: 20540482]
[17]
Kawauchi, H.; Yanai, K.; Wang, D.Y.; Itahashi, K.; Okubo, K. Antihistamines for allergic rhinitis treatment from the viewpoint of non-sedative properties. Int. J. Mol. Sci., 2019, 20(1), 213.
[http://dx.doi.org/10.3390/ijms20010213] [PMID: 30626077]
[18]
Gilbert, C.; Mazzotta, P.; Loebstein, R.; Koren, G. Fetal safety of drugs used in the treatment of allergic rhinitis: A critical review. Drug Saf., 2005, 28(8), 707-719.
[http://dx.doi.org/10.2165/00002018-200528080-00005] [PMID: 16048356]
[19]
Unal, M.; Hafiz, G. The role of antihistamines in the management of allergic rhinitis. Curr. Med. Chem. Anti Inflamm. Anti Allergy Agents, 2005, 4(5), 477-480.
[http://dx.doi.org/10.2174/156801405774330349]
[20]
Sheryl Beard, MD Rhinitis, primary care: Clinics in office practice. 2014, 41(1), 33-46.
[21]
Del Cuvillo, A.; Sastre, J.; Montoro, J.; Jáuregui, I.; Ferrer, M.; Dávila, I.; Bartra, J.; Mullol, J.; Valero, A. Use of antihistamines in pediatrics. J. Investig. Allergol. Clin. Immunol., 2007, 17(2), 28-40.
[PMID: 18225708]
[22]
Fitzsimons, R.; van der Poel, L.A.; Thornhill, W.; du Toit, G.; Shah, N.; Brough, H.A. Antihistamine use in children. Arch. Dis. Child. Educ. Pract. Ed., 2015, 100(3), 122-131.
[http://dx.doi.org/10.1136/archdischild-2013-304446] [PMID: 25147323]
[23]
Etwel, F.; Faught, L.H.; Rieder, M.J.; Koren, G. The risk of adverse pregnancy outcome after first trimester exposure to H1antihistamines: A systematic review and meta-analysis. Drug Saf., 2017, 40(2), 121-132.
[http://dx.doi.org/10.1007/s40264-016-0479-9] [PMID: 27878468]
[24]
Gonzalez-Estrada, A.; Geraci, S.A. Allergy medications during pregnancy. Am. J. Med. Sci., 2016, 352(3), 326-331.
[http://dx.doi.org/10.1016/j.amjms.2016.05.030] [PMID: 27650241]
[25]
Kaliner, MA H1-antihistamines in the elderly. Histamine and H1-antihistamines in allergic disease, 2002, 481-498.
[26]
Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; Yuan, M.L.; Zhang, Y.L.; Dai, F.H.; Liu, Y.; Wang, Q.M.; Zheng, J.J.; Xu, L.; Holmes, E.C.; Zhang, Y.Z. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798), 265-269.
[http://dx.doi.org/10.1038/s41586-020-2008-3] [PMID: 32015508]
[27]
Ennis, M.; Tiligada, K. Histamine receptors and COVID-19. Inflamm. Res., 2021, 70(1), 67-75.
[http://dx.doi.org/10.1007/s00011-020-01422-1] [PMID: 33206207]
[28]
Shereen, M.A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J. Adv. Res., 2020, 24, 91-98.
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[29]
Hogan, R.B., II; Hogan, R.B., III; Cannon, T.; Rappai, M.; Studdard, J.; Paul, D.; Dooley, T.P. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulm. Pharmacol. Ther., 2020, 63, 101942.
[http://dx.doi.org/10.1016/j.pupt.2020.101942] [PMID: 32871242]
[30]
Morán Blanco, J.I.; Alvarenga Bonilla, J.A.; Homma, S.; Suzuki, K.; Fremont-Smith, P.; Villar Gómez de las Heras, K. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients. Pulm. Pharmacol. Ther., 2021, 67, 101989.
[http://dx.doi.org/10.1016/j.pupt.2021.101989] [PMID: 33465426]
[31]
Fritz, I.; Wagner, P.; Olsson, H. Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl. Oncol., 2021, 14(4), 101029.
[http://dx.doi.org/10.1016/j.tranon.2021.101029] [PMID: 33550204]
[32]
Fritz, I.; Wagner, P.; Broberg, P.; Einefors, R.; Olsson, H. Desloratadine and loratadine stand out among common H 1 -antihistamines for association with improved breast cancer survival. Acta Oncol., 2020, 59(9), 1103-1109.
[http://dx.doi.org/10.1080/0284186X.2020.1769185] [PMID: 32459128]
[33]
Nolen, T. Sedative effects of antihistamines: Safety, performance, learning, and quality of life. Clin. Ther., 1997, 19(1), 39-55.
[http://dx.doi.org/10.1016/S0149-2918(97)80071-9] [PMID: 9083707]
[34]
Wang, D.Y.; Wang, X.Y.; Lim-Jurado, M.; Prepageran, N.; Tantilipikorn, P. Treatment of allergic rhinitis and urticaria: A review of the newest antihistamine drug bilastine. Ther. Clin. Risk Manag., 2016, 12, 585-597.
[http://dx.doi.org/10.2147/TCRM.S105189] [PMID: 27110120]
[35]
Available from: https://www.uspharmacist.com/article/helpingpeople-manage-insomnia
[36]
Morin, C.M.; Benca, R. Chronic insomnia. Lancet, 2012, 379(9821), 1129-1141.
[http://dx.doi.org/10.1016/S0140-6736(11)60750-2] [PMID: 22265700]
[37]
Matheson, E.; Hainer, B.L. Insomnia: Pharmacologic therapy. Am. Fam. Physician, 2017, 96(1), 29-35.
[PMID: 28671376]
[38]
Stevenson, J.; Cornah, D.; Evrard, P.; Vanderheyden, V.; Billard, C.; Bax, M.; Van Hout, A. Long-term evaluation of the impact of the h1-receptor antagonist cetirizine on the behavioral, cognitive, and psychomotor development of very young children with atopic dermatitis. Pediatr. Res., 2002, 52(2), 251-257.
[http://dx.doi.org/10.1203/00006450-200208000-00018] [PMID: 12149503]

Rights & Permissions Print Cite
Article Metrics
28
2
© 2024 Bentham Science Publishers | Privacy Policy